CGRP vs Met-Enkephalin

Binds CLR/RAMP1 receptor complex. Causes vasodilation via cAMP/PKA/nitric oxide pathway. Modulates nociceptive signaling in the trigeminal system. Promotes bone healing and has anti-inflammatory effects in peripheral tissues.

CGRP (calcitonin gene-related peptide) is a 37-amino-acid endogenous neuropeptide produced by alternative splicing of the calcitonin gene, expressed predominantly in sensory neurons of the trigeminal system and peripheral vasculature, where it functions as a potent vasodilator and pain neuromodulator central to migraine pathophysiology. CGRP activates its receptor complex (CLR/RAMP1) to mediate vasodilation and nociceptive signal amplification; during migraine attacks, trigeminal activation releases CGRP at elevated plasma concentrations, and blockade of this pathway has been established as the primary validated pharmacological target for modern preventive migraine therapy. Phase 3 randomized controlled trials published in the New England Journal of Medicine and the Lancet — including the STRIVE trial (Goadsby et al. 2017) and a Phase 3b study in treatment-refractory patients — demonstrated that anti-CGRP monoclonal antibodies significantly reduced monthly migraine days versus placebo, validating the pathway and supporting FDA approval of erenumab, fremanezumab, and galcanezumab. CGRP itself is an endogenous neuropeptide and is not a therapeutic agent that is compounded or administered by providers; the FDA-approved interventions are monoclonal antibody and small-molecule receptor antagonists available by prescription, and exogenous CGRP peptide is exclusively a research tool compound used in vasodilatory and pain signaling pharmacology studies.

Binds OGF receptors (zeta opioid receptors) on cell nuclei, regulating DNA synthesis and cell proliferation in a tonic inhibitory manner. Also binds delta opioid receptors. Intermittent blockade by low-dose naltrexone upregulates receptor expression and endogenous MENK tone.

Methionine enkephalin (Met-enkephalin; opioid growth factor, OGF) is an endogenous pentapeptide (Tyr-Gly-Gly-Phe-Met) that acts at classical mu- and delta-opioid receptors for pain modulation and, in its OGF role, functions as a tonic inhibitor of cell proliferation through interactions with the nuclear OGF receptor (OGFr, the zeta-opioid receptor), a pathway with distinct biological implications from classical analgesic opioid signaling. The OGF-OGFr axis operates as an endogenous homeostatic brake on cell cycle progression: OGF binds OGFr in the nucleus to upregulate cyclin-dependent kinase inhibitors p16 and p21, inhibiting S-phase entry; this mechanism has been characterized in models of wound repair, organ development, and immune cell regulation. Research from the Zagon laboratory has described the OGF-OGFr axis as a broad homeostatic regulator of cell proliferation and has established that the duration of opioid receptor blockade determines biotherapeutic response magnitude — the mechanistic basis for proposed low-dose naltrexone-mediated OGF upregulation in inflammatory and neoplastic conditions. Methionine enkephalin has no FDA-approved therapeutic applications as an exogenous agent; the OGF pathway has been characterized through preclinical and early-stage research, and exogenous OGF administration for any indication has not established a human clinical evidence base or received regulatory approval.